Stoke Therapeutics CMO sells 7,228 STOK shares

Stoke Therapeutics Chief Medical Officer Barry Ticho reported open‑market sales of company stock.

Rhea-AI Filing Summary

Stoke Therapeutics Chief Medical Officer Barry Ticho reported open‑market sales of company stock. On July 1, 2026, he sold a total of 7,228 shares of Common Stock in two transactions.

The first sale covered 6,728 shares at a weighted average price of $32.615 per share, and the second sale covered 500 shares at a weighted average price of $33.2678 per share. The filing notes these trades were executed under a Rule 10b5-1 trading plan adopted on November 19, 2025, indicating they were pre‑scheduled rather than discretionary.

Insider Trade Summary 10b5-1

Net Seller: 7,228 shares

Net Sell 2 txns

Insider Ticho Barry

Role CHIEF MEDICAL OFFICER

Sold 7,228 shs ($236K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,728	$32.615	$219K
Sale	Common Stock	500	$33.2678	$17K

Holdings After Transaction: Common Stock — 27,598 shares (Direct)

Footnotes (3)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.18 to $33.05 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.23 to $33.37 per share, inclusive.

Key Figures

Total shares sold: 7,228 shares First block weighted average price: $32.615 per share Second block weighted average price: $33.2678 per share +3 more

6 metrics

Total shares sold 7,228 shares Open-market sales by CMO on July 1, 2026

First block weighted average price $32.615 per share 6,728-share sale of Common Stock

Second block weighted average price $33.2678 per share 500-share sale of Common Stock

Price range block one $32.18–$33.05 per share Multiple transactions summarized as weighted average

Price range block two $33.23–$33.37 per share Multiple transactions summarized as weighted average

10b5-1 plan adoption date November 19, 2025 Plan governing the July 1, 2026 sales

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, Common Stock

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Stoke Therapeutics (STOK) report for Barry Ticho?

Stoke Therapeutics reported that Chief Medical Officer Barry Ticho sold 7,228 shares of Common Stock. The sales occurred in two open‑market transactions on July 1, 2026, and were executed under a pre‑established Rule 10b5‑1 trading plan.

How many Stoke Therapeutics (STOK) shares did Barry Ticho sell and at what prices?

Barry Ticho sold 7,228 shares of Stoke Therapeutics Common Stock. One block of 6,728 shares had a weighted average price of $32.615, and a second block of 500 shares had a weighted average price of $33.2678, both in open‑market sales.

When did the recent Stoke Therapeutics (STOK) insider stock sales take place?

The reported insider stock sales took place on July 1, 2026. On that date, Chief Medical Officer Barry Ticho completed two open‑market transactions totaling 7,228 shares of Stoke Therapeutics Common Stock at weighted average prices above $32 per share.

Were Barry Ticho’s Stoke Therapeutics (STOK) stock sales made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were executed pursuant to a Rule 10b5‑1 trading plan adopted on November 19, 2025. Such plans pre‑schedule trades, indicating these sales were arranged in advance rather than timed in response to short‑term company developments.

What price ranges applied to Barry Ticho’s Stoke Therapeutics (STOK) share sales?

The filing explains that reported prices are weighted averages over multiple trades. One group of sales occurred between $32.18 and $33.05 per share, while the other group occurred between $33.23 and $33.37 per share, all involving Stoke Therapeutics Common Stock.

What role does Barry Ticho hold at Stoke Therapeutics (STOK) in this Form 4 filing?

In this Form 4, Barry Ticho is identified as an officer of Stoke Therapeutics, serving as Chief Medical Officer. The reported insider transactions therefore reflect trading activity by a senior executive involved in overseeing the company’s medical and clinical functions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/06/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ticho Barry

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		S(1)		6,728	D	$32.615(2)	28,098	D
Common Stock	07/01/2026		S(1)		500	D	$33.2678(3)	27,598	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.18 to $33.05 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.23 to $33.37 per share, inclusive.

	/s/ Jonathan Allan, Attorney-in-Fact	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)